Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice
Author:
Nissen-Meyer Lise Sofie Haug1, Jemtland Rune2, Gautvik Vigdis T.1, Pedersen Mona E.1, Paro Rita1, Fortunati Dario1, Pierroz Dominique D.3, Stadelmann Vincent A.4, Reppe Sjur1, Reinholt Finn P.5, Del Fattore Andrea6, Rucci Nadia6, Teti Anna6, Ferrari Serge3, Gautvik Kaare M.17
Affiliation:
1. Department of Biochemistry, Institute of Basic Medical Sciences, University of Oslo, N-0317 Oslo, Norway 2. Endocrine Section, Department of Medicine, University of Oslo, Rikshospitalet-Radiumhospitalet Medical Centre, N-0027 Oslo, Norway 3. Service of Bone Diseases, WHO Collaborating Center for Osteoporosis Prevention, Geneva University Hospital, 1211 Geneva, Switzerland 4. Laboratory of Biomechanical Orthopedics, EPFL-HOSR, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland 5. Institute of Pathology, University of Oslo, and The Pathology Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, N-0027 Oslo, Norway 6. Department of Experimental Medicine, University of L'Aquila, 67100 L'Aquila, Italy 7. Department of Clinical Chemistry, Ullevål University Hospital, N-0407 Oslo, Norway
Abstract
The transcription factor Sox4 is vital for fetal development, as Sox4–/– homozygotes die in utero. Sox4 mRNA is expressed in the early embryonic growth plate and is regulated by parathyroid hormone, but its function in bone modeling/remodeling is unknown. We report that Sox4+/– mice exhibit significantly lower bone mass (by dual-energy X-ray absorptiometry) from an early age, and fail to obtain the peak bone mass of wild-type (WT) animals. Microcomputed tomography (μCT), histomorphometry and biomechanical testing of Sox4+/– bones show reduced trabecular and cortical thickness, growth plate width, ultimate force and stiffness compared with WT. Bone formation rate (BFR) in 3-month-old Sox4+/– mice is 64% lower than in WT. Primary calvarial osteoblasts from Sox4+/– mice demonstrate markedly inhibited proliferation, differentiation and mineralization. In these cultures, osterix (Osx) and osteocalcin (OCN) mRNA expression was reduced, whereas Runx2 mRNA was unaffected. No functional defects were found in osteoclasts. Silencing of Sox4 by siRNA in WT osteoblasts replicated the defects observed in Sox4+/– cells. We demonstrate inhibited formation and altered microarchitecture of bone in Sox4+/– mice versus WT, without apparent defects in bone resorption. Our results implicate the transcription factor Sox4 in regulation of bone formation, by acting upstream of Osx and independent of Runx2.
Publisher
The Company of Biologists
Reference60 articles.
1. Ahn, S. G., Kim, H. S., Jeong, S. W., Kim, B. E., Rhim, H., Shim, J. Y., Kim, J. W., Lee, J. H. and Kim, I. K. (2002). Sox-4 is a positive regulator of Hep3B and HepG2 cells' apoptosis induced by prostaglandin (PG)A(2) and delta(12)-PGJ(2). Exp. Mol. Med.34, 243-249. 2. Billiard, J., Moran, R. A., Whitley, M. Z., Chatterjee-Kishore, M., Gillis, K., Brown, E. L., Komm, B. S. and Bodine, P. V. (2003). Transcriptional profiling of human osteoblast differentiation. J. Cell. Biochem.89, 389-400. 3. Bouxsein, M. L., Pierroz, D. D., Glatt, V., Goddard, D. S., Cavat, F., Rizzoli, R. and Ferrari, S. L. (2005). beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J. Bone Miner. Res.20, 635-643. 4. Brodt, M. D., Ellis, C. B. and Silva, M. J. (1999). Growing C57Bl/6 mice increase whole bone mechanical properties by increasing geometric and material properties. J. Bone Miner. Res.14, 2159-2166. 5. Caselli, G., Mantovanini, M., Gandolfi, C. A., Allegretti, M., Fiorentino, S., Pellegrini, L., Melillo, G., Bertini, R., Sabbatini, W., Anacardio, R. et al. (1997). Tartronates: a new generation of drugs affecting bone metabolism. J. Bone Miner. Res.12, 972-981.
Cited by
74 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|